WCM/EADO 2021 | Neoantigens for melanoma treatment

Samra Turajlic, MBBS, MRCP, PhD, Francis Crick Institute, London, UK, provides an overview of her presentation at the 2021 WCM/EADO virtual congress, which was focussed on novel therapeutic approaches involving neoantigens for melanoma. Neoantigens arise through somatic mutations in tumor cells and can elicit a downstream immune response against those tumor cells, making them an attractive target in melanoma, a highly mutated form of cancer. Dr Turajlic describes strategies under investigation which aim to exploit neoantigens for therapeutic targeting in melanoma, including neoantigen-based vaccines and T-cell therapies. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.